{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T22:31:24Z","timestamp":1794522684031,"version":"4.9.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"MO4MO and MoVa Associations"},{"name":"Gli Amici di Robi\u201d and \u201cAssociazione APS Michelangelo Barcella"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-34904-5","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T11:56:45Z","timestamp":1769687805000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pharmacological WEE1 inhibition as a strategy to overcome cisplatin resistance in non-seminoma testicular cancer: insights from preclinical models"],"prefix":"10.1038","volume":"16","author":[{"given":"Mariangela","family":"Tamburello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Boldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Abate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Valcamonico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lagan\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Cosentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazareno R.","family":"Suardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Mirabella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Sigala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"61","key":"34904_CR1","doi-asserted-by":"publisher","first-page":"104654","DOI":"10.18632\/oncotarget.20992","volume":"8","author":"M Boccellino","year":"2017","unstructured":"Boccellino, M. et al. Testicular cancer from diagnosis to epigenetic factors. Oncotarget 8(61), 104654\u2013104663 (2017).","journal-title":"Oncotarget"},{"issue":"21","key":"34904_CR2","doi-asserted-by":"publisher","first-page":"5369","DOI":"10.1158\/0008-5472.CAN-21-1452","volume":"81","author":"J King","year":"2021","unstructured":"King, J., Adra, N. & Einhorn, L. H. Testicular cancer: Biology to bedside. Cancer Res. 81(21), 5369\u20135376 (2021).","journal-title":"Cancer Res."},{"issue":"10029","key":"34904_CR3","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1016\/S0140-6736(15)00991-5","volume":"387","author":"E Rajpert-De Meyts","year":"2016","unstructured":"Rajpert-De Meyts, E. et al. Testicular germ cell tumours. Lancet 387(10029), 1762\u20131774 (2016).","journal-title":"Lancet"},{"issue":"Suppl 6","key":"34904_CR4","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/annonc\/mdt304","volume":"24","author":"J Oldenburg","year":"2013","unstructured":"Oldenburg, J. et al. Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24(Suppl 6), 125\u2013132 (2013).","journal-title":"Ann. Oncol."},{"key":"34904_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.humpath.2018.07.016","volume":"82","author":"J Lobo","year":"2018","unstructured":"Lobo, J. et al. Testicular germ cell tumors: Revisiting a series in light of the new WHO classification and AJCC staging systems, focusing on challenges for pathologists. Hum. Pathol. 82, 113\u2013124 (2018).","journal-title":"Hum. Pathol."},{"key":"34904_CR6","doi-asserted-by":"publisher","first-page":"102054","DOI":"10.1016\/j.ctrv.2020.102054","volume":"88","author":"G de Vries","year":"2020","unstructured":"de Vries, G. et al. Testicular cancer: Determinants of cisplatin sensitivity and novel therapeutic opportunities. Cancer Treat. Rev. 88, 102054 (2020).","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"34904_CR7","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.3390\/cancers12061601","volume":"12","author":"J Lobo","year":"2020","unstructured":"Lobo, J., Jer\u00f3nimo, C. & Henrique, R. Cisplatin resistance in testicular germ cell tumors: Current challenges from various perspectives. Cancers (Basel). 12(6), 1601 (2020).","journal-title":"Cancers (Basel)"},{"issue":"3","key":"34904_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ucl.2015.04.010","volume":"42","author":"MJ O\u2019Shaughnessy","year":"2015","unstructured":"O\u2019Shaughnessy, M. J. et al. Late relapse of testicular germ cell tumors. Urol. Clin. N. Am. 42(3), 359\u2013368 (2015).","journal-title":"Urol. Clin. N. Am."},{"key":"34904_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1146\/annurev-med-081313-121208","volume":"66","author":"M Goldstein","year":"2015","unstructured":"Goldstein, M. & Kastan, M. B. The DNA damage response: Implications for tumor responses to radiation and chemotherapy. Annu. Rev. Med. 66, 129\u2013143 (2015).","journal-title":"Annu. Rev. Med."},{"key":"34904_CR10","doi-asserted-by":"crossref","unstructured":"Esposito, F. et al. Wee1 kinase: A potential target to overcome tumor resistance to therapy. Int. J. Mol. Sci. 22(19), 10689. (2021).","DOI":"10.3390\/ijms221910689"},{"issue":"7","key":"34904_CR11","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/cancers14071690","volume":"14","author":"K Funke","year":"2022","unstructured":"Funke, K. et al. Transcriptional CDK inhibitors as potential treatment option for testicular germ cell tumors. Cancers (Basel). 14(7), 1690 (2022).","journal-title":"Cancers (Basel)"},{"issue":"4","key":"34904_CR12","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.clgc.2021.01.006","volume":"19","author":"E Rossini","year":"2021","unstructured":"Rossini, E. et al. Cisplatin cytotoxicity in human testicular germ cell tumor cell lines is enhanced by the CDK4\/6 inhibitor palbociclib. Clin. Genitourin. Cancer. 19(4), 316\u2013324 (2021).","journal-title":"Clin. Genitourin. Cancer"},{"issue":"5","key":"34904_CR13","doi-asserted-by":"publisher","first-page":"368","DOI":"10.3390\/cells13050368","volume":"13","author":"E Rossini","year":"2024","unstructured":"Rossini, E. et al. The CDK inhibitor dinaciclib improves cisplatin response in nonseminomatous testicular cancer: A preclinical study. Cells 13(5), 368 (2024).","journal-title":"Cells"},{"issue":"1","key":"34904_CR14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13045-020-00959-2","volume":"13","author":"A Ghelli Luserna di Ror\u00e0","year":"2020","unstructured":"Ghelli Luserna di Ror\u00e0, A. et al. A WEE1 family business: Regulation of mitosis, cancer progression, and therapeutic target. J. Hematol. Oncol. 13(1), 126 (2020).","journal-title":"J. Hematol. Oncol."},{"issue":"6367","key":"34904_CR15","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/356353a0","volume":"356","author":"R Rowley","year":"1992","unstructured":"Rowley, R., Hudson, J. & Young, P. G. The wee1 protein kinase is required for radiation-induced mitotic delay. Nature 356(6367), 353\u2013355 (1992).","journal-title":"Nature"},{"key":"34904_CR16","doi-asserted-by":"publisher","first-page":"104710","DOI":"10.1016\/j.critrevonc.2025.104710","volume":"211","author":"T Krishnapriya","year":"2025","unstructured":"Krishnapriya, T. et al. WEE1 inhibition in cancer therapy: Mechanisms, synergies, preclinical insights, and clinical trials. Crit. Rev. Oncol. Hematol. 211, 104710 (2025).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"30","key":"34904_CR17","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1200\/JCO.2014.60.4009","volume":"33","author":"K Do","year":"2015","unstructured":"Do, K. et al. Phase I study of single-agent AZD1775 (MK-1775), a Wee1 kinase inhibitor, in patients with refractory solid tumors. J. Clin. Oncol. 33(30), 3409\u20133415 (2015).","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"34904_CR18","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-17-3796","volume":"24","author":"E M\u00e9ndez","year":"2018","unstructured":"M\u00e9ndez, E. et al. A phase I clinical trial of AZD1775 in combination with neoadjuvant weekly docetaxel and cisplatin before definitive therapy in head and neck squamous cell carcinoma. Clin. Cancer Res. 24 (12), 2740\u20132748 (2018).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"34904_CR19","first-page":"36","volume":"28","author":"KN Moore","year":"2022","unstructured":"Moore, K. N. et al. Adavosertib with chemotherapy in patients with primary platinum-resistant ovarian, fallopian tube, or peritoneal cancer: An open-label, four-arm, phase II study. Clin. Cancer Res. 28(1), 36\u201344 (2022).","journal-title":"Cancer Res."},{"issue":"29","key":"34904_CR20","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1200\/JCO.19.00730","volume":"37","author":"KC Cuneo","year":"2019","unstructured":"Cuneo, K. C. et al. Dose escalation trial of the Wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer. J. Clin. Oncol. 37(29), 2643\u20132650 (2019).","journal-title":"J. Clin. Oncol."},{"key":"34904_CR21","doi-asserted-by":"crossref","unstructured":"Liu, J. F. et al. A Phase II Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Recurrent Uterine Serous Carcinoma (American Society of Clinical Oncology, 2020).","DOI":"10.1016\/j.ygyno.2020.06.009"},{"key":"34904_CR22","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.ygyno.2023.06.512","volume":"176","author":"J Liu","year":"2023","unstructured":"Liu, J. et al. A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma (039). Gynecol. Oncol. 176, S33\u2013S35 (2023).","journal-title":"Gynecol. Oncol."},{"issue":"16_suppl","key":"34904_CR23","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1200\/JCO.2024.42.16_suppl.3120","volume":"42","author":"KP Papadopoulos","year":"2024","unstructured":"Papadopoulos, K. P. et al. Results of a phase 1, dose-finding study of Debio 0123 as monotherapy in adult patients with advanced solid tumors: Safety, pharmacokinetic, and preliminary antitumor activity data. J. Clin. Oncol. 42(16_suppl), 3120\u20133120 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"34904_CR24","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/S0360-3016(98)00065-0","volume":"41","author":"H Burger","year":"1998","unstructured":"Burger, H. et al. Expression of p53, p21\/WAF\/CIP, Bcl-2, Bax, Bcl-x, and bak in radiation-induced apoptosis in testicular germ cell tumor lines. Int. J. Radiat. Oncol. Biol. Phys. 41(2), 415\u2013424 (1998).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"21","key":"34904_CR25","doi-asserted-by":"publisher","first-page":"11774","DOI":"10.3390\/ijms222111774","volume":"22","author":"DM Timmerman","year":"2021","unstructured":"Timmerman, D. M. et al. The role of TP53 in cisplatin resistance in mediastinal and testicular germ cell tumors. Int. J. Mol. Sci. 22(21), 11774 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"34904_CR26","first-page":"5813292","volume":"2018","author":"D Chen","year":"2018","unstructured":"Chen, D. et al. Wee1 inhibitor AZD1775 combined with cisplatin potentiates anticancer activity against gastric cancer by increasing DNA damage and cell apoptosis. Biomed. Res. Int. 2018, 5813292 (2018).","journal-title":"Biomed. Res. Int."},{"issue":"13","key":"34904_CR27","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1158\/1078-0432.CCR-10-2537","volume":"17","author":"PC De Witt Hamer","year":"2011","unstructured":"De Witt Hamer, P. C. et al. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe. Clin. Cancer Res. 17(13), 4200\u20134207 (2011).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"34904_CR28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ygyno.2014.07.102","volume":"135","author":"A Slipicevic","year":"2014","unstructured":"Slipicevic, A. et al. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. Gynecol. Oncol. 135(1), 118\u2013124 (2014).","journal-title":"Gynecol. Oncol."},{"issue":"36","key":"34904_CR29","doi-asserted-by":"publisher","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","volume":"34","author":"S Leijen","year":"2016","unstructured":"Leijen, S. et al. Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J. Clin. Oncol. 34(36), 4354\u20134361 (2016).","journal-title":"J. Clin. Oncol."},{"key":"34904_CR30","doi-asserted-by":"publisher","first-page":"100003","DOI":"10.1016\/j.namjnl.2024.100003","volume":"1","author":"V Anu","year":"2025","unstructured":"Anu, V. et al. New frontiers in anti-cancer drug testing: the need for a relevant in vitro testing model. NAM J. 1, 100003 (2025).","journal-title":"NAM J."},{"issue":"10","key":"34904_CR31","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.tips.2016.06.006","volume":"37","author":"CJ Matheson","year":"2016","unstructured":"Matheson, C. J., Backos, D. S. & Reigan, P. Targeting WEE1 kinase in cancer. Trends Pharmacol. Sci. 37(10), 872\u2013881 (2016).","journal-title":"Trends Pharmacol. Sci."},{"issue":"9","key":"34904_CR32","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/PAI.0000000000000499","volume":"26","author":"\u0130 Elmaci","year":"2018","unstructured":"Elmaci, \u0130. et al. Phosphorylated histone H3 (PHH3) as a novel cell proliferation marker and prognosticator for meningeal tumors: A short review. Appl. Immunohistochem. Mol. Morphol. 26(9), 627\u2013631 (2018).","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"9","key":"34904_CR33","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.dnarep.2009.04.012","volume":"8","author":"TH Stracker","year":"2009","unstructured":"Stracker, T. H., Usui, T. & Petrini, J. H. Taking the time to make important decisions: The checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair. (Amst). 8(9), 1047\u20131054 (2009).","journal-title":"DNA Repair. (Amst.)"},{"issue":"5","key":"34904_CR34","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.tcb.2009.03.001","volume":"19","author":"H van Attikum","year":"2009","unstructured":"van Attikum, H. & Gasser, S. M. Crosstalk between histone modifications during the DNA damage response. Trends Cell. Biol. 19(5), 207\u2013217 (2009).","journal-title":"Trends Cell. Biol."},{"issue":"12","key":"34904_CR35","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1038\/bjc.2011.456","volume":"105","author":"Y Pan","year":"2011","unstructured":"Pan, Y. et al. Evaluation of pharmacodynamic biomarkers in a phase 1a trial of dulanermin (rhApo2L\/TRAIL) in patients with advanced tumours. Br. J. Cancer. 105(12), 1830\u20131838 (2011).","journal-title":"Br. J. Cancer"},{"issue":"8","key":"34904_CR36","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/FPC.0b013e3283481967","volume":"21","author":"Y Wen","year":"2011","unstructured":"Wen, Y. et al. Chemotherapeutic-induced apoptosis: A phenotype for pharmacogenomics studies. Pharmacogen Genom.. 21(8), 476\u2013488 (2011).","journal-title":"Pharmacogen Genom."},{"issue":"4","key":"34904_CR37","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.annonc.2022.01.002","volume":"33","author":"J Oldenburg","year":"2022","unstructured":"Oldenburg, J. et al. Testicular seminoma and non-seminoma: ESMO-EURACAN clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33(4), 362\u2013375 (2022).","journal-title":"Ann. Oncol."},{"issue":"4","key":"34904_CR38","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/(SICI)1097-0215(19971114)73:4<592::AID-IJC22>3.0.CO;2-A","volume":"73","author":"H Burger","year":"1997","unstructured":"Burger, H. et al. Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int. J. Cancer. 73(4), 592\u2013599 (1997).","journal-title":"Int. J. Cancer"},{"issue":"17","key":"34904_CR39","doi-asserted-by":"publisher","first-page":"5638","DOI":"10.1158\/1078-0432.CCR-11-0650","volume":"17","author":"KA Bridges","year":"2011","unstructured":"Bridges, K. A. et al. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin. Cancer Res. 17(17), 5638\u20135648 (2011).","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"34904_CR40","doi-asserted-by":"publisher","first-page":"2992","DOI":"10.1158\/1535-7163.MCT-09-0463","volume":"8","author":"H Hirai","year":"2009","unstructured":"Hirai, H. et al. Small-molecule Inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents. Mol. Cancer Ther. 8(11), 2992\u20133000 (2009).","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"34904_CR41","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jtho.2019.01.028","volume":"14","author":"WH Hsu","year":"2019","unstructured":"Hsu, W. H. et al. Checkpoint kinase 1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in SCLC by promoting mitotic cell death. J. Thorac. Oncol. 14(6), 1032\u20131045 (2019).","journal-title":"J. Thorac. Oncol."},{"issue":"9","key":"34904_CR42","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1158\/1078-0432.CCR-10-2580","volume":"17","author":"NV Rajeshkumar","year":"2011","unstructured":"Rajeshkumar, N. V. et al. MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectively in p53-deficient pancreatic cancer xenografts. Clin. Cancer Res. 17(9), 2799\u20132806 (2011).","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"34904_CR43","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.3390\/cells12111471","volume":"12","author":"YL Su","year":"2023","unstructured":"Su, Y. L. et al. Inhibiting WEE1 augments the antitumor efficacy of cisplatin in urothelial carcinoma by enhancing the DNA damage process. Cells 12(11), 1471 (2023).","journal-title":"Cells"},{"issue":"36","key":"34904_CR44","doi-asserted-by":"publisher","first-page":"4371","DOI":"10.1200\/JCO.2016.67.5991","volume":"34","author":"S Leijen","year":"2016","unstructured":"Leijen, S. et al. Phase I study evaluating WEE1 inhibitor AZD1775 as monotherapy and in combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. J. Clin. Oncol. 34(36), 4371\u20134380 (2016).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"34904_CR45","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/andr.12814","volume":"8","author":"J Lobo","year":"2020","unstructured":"Lobo, J. et al. 53 and MDM2 expression in primary and metastatic testicular germ cell tumors: Association with clinical outcome. Andrology 8(5), 1233\u20131242 (2020).","journal-title":"Andrology"},{"issue":"4","key":"34904_CR46","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1158\/1078-0432.CCR-20-3089","volume":"27","author":"TE Keenan","year":"2021","unstructured":"Keenan, T. E. et al. Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer. Clin. Cancer Res. 27(4), 983\u2013991 (2021).","journal-title":"Clin. Cancer Res."},{"key":"34904_CR47","doi-asserted-by":"crossref","unstructured":"Lheureux, S. et al. A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with Adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia (American Society of Clinical Oncology, 2019).","DOI":"10.1200\/JCO.2019.37.15_suppl.5518"},{"issue":"10271","key":"34904_CR48","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0140-6736(20)32554-X","volume":"397","author":"S Lheureux","year":"2021","unstructured":"Lheureux, S. et al. Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397(10271), 281\u2013292 (2021).","journal-title":"Lancet"},{"key":"34904_CR49","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1476-4598-10-52","volume":"10","author":"M Port","year":"2011","unstructured":"Port, M. et al. Micro-RNA expression in cisplatin resistant germ cell tumor cell lines. Mol. Cancer. 10, 52 (2011).","journal-title":"Mol. Cancer"},{"issue":"12","key":"34904_CR50","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1093\/annonc\/mdr026","volume":"22","author":"K Oechsle","year":"2011","unstructured":"Oechsle, K. et al. Preclinical and clinical activity of Sunitinib in patients with cisplatin-refractory or multiply relapsed germ cell tumors: a Canadian urologic oncology group\/German testicular cancer study group cooperative study. Ann. Oncol. 22(12), 2654\u20132660 (2011).","journal-title":"Ann. Oncol."},{"issue":"2","key":"34904_CR51","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.canlet.2012.05.009","volume":"324","author":"AE Fenske","year":"2012","unstructured":"Fenske, A. E. et al. Cisplatin resistance induced in germ cell tumour cells is due to reduced susceptibility towards cell death but not to altered DNA damage induction or repair. Cancer Lett. 324(2), 171\u2013178 (2012).","journal-title":"Cancer Lett."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34904-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34904-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34904-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:03:31Z","timestamp":1770638611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34904-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34904"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34904-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"13 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5448"}}